Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
1(10%)
Results Posted
20%(1 trials)
Terminated
3(30%)

Phase Distribution

Ph phase_1
5
50%
Ph phase_4
1
10%
Ph phase_2
4
40%

Phase Distribution

5

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(5)
Terminated(4)

Detailed Status

Completed5
Terminated3
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
62.5%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (50.0%)
Phase 24 (40.0%)
Phase 41 (10.0%)

Trials by Status

completed550%
recruiting110%
terminated330%
withdrawn110%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_1

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

NCT06321484
withdrawnphase_1

Diabetes Islet Preservation Immune Treatment

NCT02586831
terminatedphase_1

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

NCT04887259
completedphase_2

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

NCT01988506
terminatedphase_2

NY-ESO-1 T Cells in OG Cancer

NCT01795976
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06321484Phase 1

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Recruiting
NCT02586831Phase 1

Diabetes Islet Preservation Immune Treatment

Withdrawn
NCT04887259Phase 1

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Terminated
NCT01988506Phase 2

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

Completed
NCT01795976Phase 2

NY-ESO-1 T Cells in OG Cancer

Terminated
NCT02360592Phase 4

Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients

Completed
NCT00002994Phase 1

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

Completed
NCT00071890Phase 2

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

Completed
NCT00277758Phase 1

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

Terminated
NCT00196586Phase 2

Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10